Anionic Drug Delivery via Lipid-Micelle Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral delivery systems for anionic drugs, such as nucleic acids, face challenges including toxicity, instability in blood, and inefficient intracellular delivery due to the use of high amounts of cationic lipids or polymers, and struggle to form stable structures for systemic application.
Innovation Solution
A pharmaceutical composition comprising an anionic drug, a cationic lipid, and an amphiphilic block copolymer that forms a complex, which is then entrapped in a core-shell type polymeric micelle structure, reducing the amount of cationic components and enhancing stability and delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high amounts of cationic lipids or polymers are used to form complexes with anionic drugs, then intracellular delivery efficiency is improved, but toxicity increases
Solution Approach 1:
The patent uses a composite delivery system combining cationic lipids and amphiphilic block copolymers. The cationic lipid forms electrostatic complexes with anionic drugs, while the amphiphilic block copolymer forms micelles that encapsulate these complexes. This composite structure enables effective intracellular delivery while reducing the toxicity associated with using high amounts of single cationic components.
2Stability of the object's composition
If cationic lipids or polymers are used to form complexes with anionic drugs, then electrostatic stabilization is achieved, but stability in blood is insufficient
Solution Approach 1:
The patent employs a nested structure where the anionic drug is first complexed with cationic lipids to form lipoplexes, which are then encapsulated within the micelle core of amphiphilic block copolymers. This nested arrangement provides dual stabilization: electrostatic interactions at the inner level and hydrophobic/hydrophilic micellar structure at the outer level, ensuring stability in blood circulation.
3Productivity
If liposome delivery system is used for systemic application, then nucleic acid delivery is achieved, but reticuloendothelial system capture causes significant toxicity
Solution Approach 1:
The patent changes the physical and chemical parameters of the delivery system by using amphiphilic block copolymer micelles instead of traditional liposomes. The micellar structure with its hydrophobic core and hydrophilic shell, combined with the electrostatic complexation of cationic lipids with anionic drugs, creates a delivery system that avoids reticuloendothelial system capture while maintaining effective nucleic acid delivery capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable delivery and effective intracellular uptake of anionic drugs with reduced toxicity, maintaining stability in blood and body fluids, and allowing for efficient systemic application.
Implementation Method 1
a complex of cationic lipid and anionic drug
Implementation Method 2
the complex is entrapped in the micelle structure of the amphiphilic block copolymer
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are an anionic drug-containing pharmaceutical composition comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The pharmaceutical composition may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs.